Project description
Novel inhibitor for metastatic prostate and pancreatic cancer
Metastases are the leading cause of death in most cancers including prostate and pancreatic cancer. Serine protease mesotrypsin promotes tumour invasion and metastasis in prostate and pancreatic cancer animal models, making it a potential therapeutic target. In the current EU-funded PROT-RESIST project, researchers designed a novel mesotrypsin inhibitor (APPI-3M) based on the human amyloid β-protein precursor Kunitz protease inhibitor domain scaffold. Previously, this inhibitor demonstrated high affinity and binding specificity, improved proteolytic resistance and high potency in preclinical models of prostate cancer invasion and metastasis. This stage of the project will focus on the final lead optimisation of APPI-3M, followed by preparations for clinical translation as an antimetastatic therapeutic adjuvant.
Fields of science
Programme(s)
Funding Scheme
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotHost institution
84105 Beer Sheva
Israel
See on map
Beneficiaries (1)
84105 Beer Sheva
See on map